Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

被引：16

作者：

Zhang, Haozhe ^{[1
]}

Zhou, Yi ^{[1
]}

Xing, Zengzhen ^{[1
]}

Sah, Rajiv Kumar ^{[1
]}

Hu, Junqi ^{[1
]}

Hu, Hailiang ^{[1
,2
]}

机构：

[1] So Univ Sci & Technol, Sch Med, Dept Biochem, Shenzhen 518055, Peoples R China

[2] Southern Univ Sci & Technol, Key Univ Lab Metab & Hlth Guangdong, Shenzhen 518055, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 21期

基金：

中国国家自然科学基金;

关键词：

androgen metabolism; androgen receptor; anti-androgen therapy; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; UDP-GLUCURONOSYLTRANSFERASES; INDEPENDENT GROWTH; CYP17A1; INHIBITION; BACKDOOR PATHWAY; RECEPTOR; CASTRATION; TESTOSTERONE; ABIRATERONE; EXPRESSION;

D O I：

10.3390/ijms232113521

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.

引用

页数：15

共 50 条

[21] The genomic evolution of prostate cancer under the selective pressure of anti-androgen therapy
Gsponer, Joel Roman
Dietsche, Tanja
Rufle, Alexander
Lorber, Thomas
Juskevicius, Darius
Perrina, Valeria
Lenkiewicz, Elisabeth
Zellweger, Tobias
Bachmann, Alexander
Barrett, Michael T.
Rentsch, Cyrill A.
Ruiz, Christian
Bubendorf, Lukas
CANCER RESEARCH, 2014, 74 (19)
[22] Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer
Sanchez, C.
Chan, R.
Bajgain, P.
Rambally, S.
Palapattu, G.
Mims, M.
Rooney, C. M.
Leen, A. M.
Brenner, M. K.
Vera, J. F.
PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (02) : 123 - 131
[23] Transcriptional regulation of the threshold response of prostate cancer cells to the anti-androgen casodex
Jeffrey, Randy
Wang, Wei Lin Winnie
Russell, Nicholas
Roy, Somdutta
Tenniswood, Martin
FASEB JOURNAL, 2007, 21 (05): : A259 - A259
[24] Factors predicting a response to anti-androgen withdrawal maneuvers in prostate cancer patients failing combined androgen blockade
El Geneidy, M. M.
Lewis, G.
Dainer, P.
Terris, M. K.
Brown, J.
Coleman, T.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] Effect of prescription CYP3A inducers and inhibitors on response to anti-androgen therapy in prostate cancer
Mitra, Ranjana
Goodman, Oscar B., Jr.
CANCER RESEARCH, 2016, 76
[26] Anti-androgen hormonal therapy for cancer and other diseases
Student, Sebastian
Hejmo, Tomasz
Poterala-Hejmo, Aleksandra
Lesniak, Aleksandra
Buldak, Rafal
EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 866
[27] Molecular features of complete response to neoadjuvant anti-androgen therapy in high risk localized prostate cancer
Tewari, Alok
Cheung, Alexander T.
Conway, Jake
Park, Jihye
Wankowicz, Stephanie
Lis, Rosina T.
Zhang, Zhenwei
AlDubayan, Saud
McKay, Rana R.
Taplin, Mary-Ellen
Van Allen, Eliezer M.
CANCER RESEARCH, 2020, 80 (16)
[28] A TRIAL OF ANTI-ANDROGEN THERAPY FOR BREAST-CANCER
BREWIN, TB
CLINICAL ONCOLOGY, 1983, 9 (02): : 179 - 180
[29] Comparing adaptive prostate cancer cell metabolism following anti-androgen and biguanide treatment
Gunter, Jennifer H.
Philp, Lisa
Rhee, Handoo
Lee, Wendy
Hollier, Brett
Lehman, Melanie
Sadowski, Martin C.
Nelson, Colleen
BJU INTERNATIONAL, 2018, 122 : 27 - 27
[30] HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors
Armstrong, Cameron M.
Liu, Chengfei
Lou, Wei
Lombard, Alan P.
Evans, Christopher
Gao, Allen C.
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →